Prostate cancer therapy - Debiopharm

Drug Profile

Prostate cancer therapy - Debiopharm

Alternative Names: E2 agonist/GnRH agonist - Debiopharm; Estrogen agonist/gonadotrophin releasing hormone agonist - Debiopharm; GnRH agonist/E2 agonist - Debiopharm; Gonadotrophin releasing hormone agonist/estrogen agonist - Debiopharm; TRIO; TRIO - Debiopharm

Latest Information Update: 12 Aug 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Debiopharm
  • Class Hormones
  • Mechanism of Action Estrogen receptor agonists; Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 05 Sep 2005 Phase-I/II clinical trials in Prostate cancer in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top